Axillary recurrence rate after negative sentinel node biopsy in breast cancer - Three-year follow-up of the Swedish Multicenter Cohort Study
(2008) In Annals of Surgery 247(1). p.150-156- Abstract
- Background: Sentinel lymph node biopsy is an established staging method in early breast cancer. After a negative biopsy, most institutions will not perform a completion axillary dissection. The present study reports the current axillary recurrence (AR) rate, overall and disease-free survival in the Swedish Multicenter Cohort Study. Methods: From 3534 patients with primary breast cancer <= 3 cm prospectively enrolled in the Swedish multicenter cohort study, 2246 with a negative sentinel node biopsy and no further axillary surgery were selected. Follow-up consisted of annual clinical examination and mammography. Twenty-six hospitals and 131 surgeons contributed to patient accrual. Results: After a median follow-up time of 37 months... (More)
- Background: Sentinel lymph node biopsy is an established staging method in early breast cancer. After a negative biopsy, most institutions will not perform a completion axillary dissection. The present study reports the current axillary recurrence (AR) rate, overall and disease-free survival in the Swedish Multicenter Cohort Study. Methods: From 3534 patients with primary breast cancer <= 3 cm prospectively enrolled in the Swedish multicenter cohort study, 2246 with a negative sentinel node biopsy and no further axillary surgery were selected. Follow-up consisted of annual clinical examination and mammography. Twenty-six hospitals and 131 surgeons contributed to patient accrual. Results: After a median follow-up time of 37 months (0-75), the axilla was the sole initial site of recurrence in 13 patients (13 of 2246, 0.6%). In another 7 patients, axillary relapse occurred after or concurrently with a local recurrence in the breast, and in a further 7 cases, it coincided with distant or extra-axillary lymphatic metastases. Thus, a total of 27 ARs were identified (27 of 2246, 1.2%). The overall 5-year survival was 91.6% and disease-free survival 92.1%. Conclusions: This is the first report from a national multicenter study that covers, not only highly specialized institutions but also small community hospitals with just a few procedures per year. Despite this heterogeneous background, the results lie well within the range of AR rates published internationally (0%-3.6%). The sentinel node biopsy procedure seems to be safe in a multicenter setting. Nevertheless, long-term follow-up data should be awaited before firm conclusions are drawn. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1200246
- author
- Bergkvist, Leif ; de Boniface, Jana ; Jönsson, Per-Ebbe LU ; Ingvar, Christian LU ; Liljegren, Göran and Frisell, Jan
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Surgery
- volume
- 247
- issue
- 1
- pages
- 150 - 156
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- wos:000251982400022
- scopus:37549047990
- pmid:18156935
- ISSN
- 1528-1140
- DOI
- 10.1097/SLA.0b013e318153ff40
- language
- English
- LU publication?
- yes
- id
- 7af04562-43bb-472b-bf62-7bcaf518a325 (old id 1200246)
- date added to LUP
- 2016-04-01 12:36:34
- date last changed
- 2022-03-13 20:16:29
@article{7af04562-43bb-472b-bf62-7bcaf518a325, abstract = {{Background: Sentinel lymph node biopsy is an established staging method in early breast cancer. After a negative biopsy, most institutions will not perform a completion axillary dissection. The present study reports the current axillary recurrence (AR) rate, overall and disease-free survival in the Swedish Multicenter Cohort Study. Methods: From 3534 patients with primary breast cancer <= 3 cm prospectively enrolled in the Swedish multicenter cohort study, 2246 with a negative sentinel node biopsy and no further axillary surgery were selected. Follow-up consisted of annual clinical examination and mammography. Twenty-six hospitals and 131 surgeons contributed to patient accrual. Results: After a median follow-up time of 37 months (0-75), the axilla was the sole initial site of recurrence in 13 patients (13 of 2246, 0.6%). In another 7 patients, axillary relapse occurred after or concurrently with a local recurrence in the breast, and in a further 7 cases, it coincided with distant or extra-axillary lymphatic metastases. Thus, a total of 27 ARs were identified (27 of 2246, 1.2%). The overall 5-year survival was 91.6% and disease-free survival 92.1%. Conclusions: This is the first report from a national multicenter study that covers, not only highly specialized institutions but also small community hospitals with just a few procedures per year. Despite this heterogeneous background, the results lie well within the range of AR rates published internationally (0%-3.6%). The sentinel node biopsy procedure seems to be safe in a multicenter setting. Nevertheless, long-term follow-up data should be awaited before firm conclusions are drawn.}}, author = {{Bergkvist, Leif and de Boniface, Jana and Jönsson, Per-Ebbe and Ingvar, Christian and Liljegren, Göran and Frisell, Jan}}, issn = {{1528-1140}}, language = {{eng}}, number = {{1}}, pages = {{150--156}}, publisher = {{Lippincott Williams & Wilkins}}, series = {{Annals of Surgery}}, title = {{Axillary recurrence rate after negative sentinel node biopsy in breast cancer - Three-year follow-up of the Swedish Multicenter Cohort Study}}, url = {{http://dx.doi.org/10.1097/SLA.0b013e318153ff40}}, doi = {{10.1097/SLA.0b013e318153ff40}}, volume = {{247}}, year = {{2008}}, }